Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HKSE:08189's EV-to-FCF is ranked worse than 100% of 131
companies
in the Agriculture industry
Industry Median: 17.29
vs HKSE:08189: -9.35
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Tianjin TEDA Biomedical Engineering Co (HKSE:08189) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Tianjin TEDA Biomedical Engineering Co's PE Ratio (TTM) for today is calculated as:
Tianjin TEDA Biomedical Engineering Co's share price for today is HK$0.255.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tianjin TEDA Biomedical Engineering Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.048.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Tianjin TEDA Biomedical Engineering Co EV-to-FCF Related Terms
Tianjin TEDA Biomedical Engineering Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tianjin TEDA Biomedical Engineering Co EV-to-FCF Chart
Tianjin TEDA Biomedical Engineering Co Annual Data
For the Agricultural Inputs subindustry, Tianjin TEDA Biomedical Engineering Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tianjin TEDA Biomedical Engineering Co EV-to-FCF vs Agriculture Industry
Tianjin TEDA Biomedical Engineering Co's current Enterprise Value is HK$638.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tianjin TEDA Biomedical Engineering Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-68.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tianjin TEDA Biomedical Engineering Co (HKSE:08189) has a EV-to-FCF of -9.35 as of Aug. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Tianjin TEDA Biomedical Engineering Co and its competitors. According to the industry distribution chart, Tianjin TEDA Biomedical Engineering Co ranks #999999 out of 131 companies in the Agriculture industry.
Is Tianjin TEDA Biomedical Engineering Co's EV-to-FCF too high?
Tianjin TEDA Biomedical Engineering Co's current EV-to-FCF is -9.35. Based on the distribution chart, Tianjin TEDA Biomedical Engineering Co ranks #999999 out of 131 companies in the Agriculture industry, which is in the bottom quartile relative to peers. Overall, Tianjin TEDA Biomedical Engineering Co has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tianjin TEDA Biomedical Engineering Co's EV-to-FCF compare to CTVA and CF?
According to the Agriculture industry distribution chart, Tianjin TEDA Biomedical Engineering Co ranks #999999 out of 131 companies for EV-to-FCF. This places Tianjin TEDA Biomedical Engineering Co in the lower half of its industry. The industry median EV-to-FCF is 17.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for an Agriculture company?
The median EV-to-FCF among Agriculture companies is 17.29, based on 131 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Tianjin TEDA Biomedical Engineering Co and its competitors. For the Agriculture industry, the median EV-to-FCF is 17.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tianjin TEDA Biomedical Engineering Co's current EV-to-FCF is -9.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianjin TEDA Biomedical Engineering Co stock overvalued right now?
Based on GuruFocus' analysis, Tianjin TEDA Biomedical Engineering Co (HKSE:08189) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.19, compared to a current price of HK$0.26 — trading 34.2% above its estimated fair value. The current EV-to-FCF is -9.35. Tianjin TEDA Biomedical Engineering Co's overall GF Score™ is 28/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Tianjin TEDA Biomedical Engineering Co (HKSE:08189), the current EV-to-FCF is -9.35 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tianjin TEDA Biomedical Engineering Co (HKSE:08189) Overvalued in 2026?
Based on GuruFocus' analysis, Tianjin TEDA Biomedical Engineering Co stock appears to be overvalued.
The current stock price of HK$0.26 is trading 34.2% above its estimated GF Value™ of HK$0.19.
GuruFocus considers Tianjin TEDA Biomedical Engineering Co to be Significantly Overvalued.
Key valuation signals for HKSE:08189:
EV-to-FCF: -9.35
GF Value™: HK$0.19 vs. price of HK$0.26 (34.2% above fair value)
No single metric tells the full story. See the HKSE:08189 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tianjin TEDA Biomedical Engineering Co Ltd principally engages in manufacture and sale of biological compound fertiliser products and elderly care and health care services and related products. The group is principally engaged in manufacturing and selling biological compound fertilisers, AI health & elderly care products and services. It operates in two segments namely; fertilisers products; and AI health & elderly care products and services. The company generates a majority of its revenue from the Fertilisers products segment. The People's Republic of China is the primary geographical market for the company.
28GF Score
Get the complete analysis for HKSE:08189
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08189 has been successfully added to your 
